After the Pandemic, Antibody R&D Remains Key
Summary: The onslaught of a global pandemic triggered a frenzy of R&D activity in the industry. But where we saw a revolution in vaccine development in record time, finding new drugs to effectively fight the virus remained difficult and fraught with failure and half-measures of success. Nevertheless, a group of players is still actively engaged in developing a new generation of antibodies to fight this virus, and others to come. In this webinar, key leaders in the field talk about where this is headed, and how it may more broadly affect everyone doing antibody research and development.